Media Coverage

04-Dec-2017

Sienna Cancer Diagnostics actively seeking acquisitions to drive revenue growth - CEO

Journalist Louise Weihart from the Mergermarket Sydney office: Sienna Cancer Diagnostics [ASX:SDX], an Australian diagnostic technology company, is actively seeking acquisitions to expand its product offering and drive revenue growth, said Chief Executive Officer Matthew Hoskin...



13/11/2017

Johns Hopkins Hospital Study Data to be Presented at USCAP 2018

An abstract discussing the results of a study performed by researchers at The Johns Hopkins Hospital in Baltimore, USA, has been accepted by the United States and Canadian Academy of Pathology (USCAP) for presentation at their annual conference in March 2018. 



08/11/2017

John Hopkins completes Sienna bladder cancer test study

Sienna says that Johns Hopkins Hospital has completed a 500-patient study testing of its telomerase-based in-vitro diagnostic for bladder cancer.

Sienna said that the Baltimore, Maryland-based Johns Hopkins Hospital study investigated the presence of human telomerase reverse transcriptase (hTERT) a cancer-related biomarker in urothelial cells.



08/11/2017

Sienna Announces Johns Hopkins Hospital Study Data to be Presented at USCAP 2018

An abstract discussing the results of a study performed by researchers at Johns Hopkins Hospital in Baltimore, USA, has been accepted by the United States and Canadian Academy of Pathology (USCAP) for presentation at their annual conference in March 2018.


03/11/2017

Tissue Diagnostics Market Worth 5.14 Billion USD by 2022

New market report released by MarketsAndMarkets lists Sienna Cancer Diagnostics amongst key players in the growing diagnostics market. 


October 2017

Connecting Biotech Students with Industry

Sienna, along with others including CSL, Cell Therapies and Trajan, engaged in student projects as part of the Master of Biotechnology program at University of Melbourne.


18/10/2017

Sienna Cancer Diagnostics, Appendix 4C - Quarterly Cash Flow Report

FNN article covering the release of Sienna's 4C for the quarter ending Sept 2017. The cash balance at 30 September was $4.1 million, with net cash inflow for the quarter totalling $3.4 million. New capital issued through the Company’s IPO contributed $4.4 million during the quarter and receipts from product sales were $243,000.
 


27/09/2017

Sienna Cancer Diagnostics (ASX:SDX) talks IVD test sales

In this interview with Jessica Amir from Finance News Network, Sienna CEO Matthew Hoskin highlights FY17 results and speaks to the process that drove strong sales of Sienna’s in vitro diagnostic (IVD) test. Additionally, he covers the Company’s rising position in the US and European Union markets and outlines future product developments for the organization.


26/09/2017

Sienna appoints exclusive distributor for Denmark and Sweden

Article from Ausbiotech's Biotech Dispatch covering Sienna's distribution agreement with Axlab for Denmark and Sweden. 


25/09/2017

Sienna Diagnostics: Exclusive Distributor Appointed for Denmark and Sweden

Article from BioMelbourne Network describing Sienna's new distribution agreemnt with AxLab


25/09/2017

Sienna Appoints Denmark and Sweden Distributor

In this edition of Morgans Daily, a brief update was provided on Sienna’s appointment of Denmark-based Axlab as the exclusive distributor for its adjunct bladder cancer test in Denmark and Sweden.


25/09/2017

Sienna Cancer Diagnostics Announces Exclusive Distributor Appointed for Denmark and Sweden

On Monday 25 September, Sienna announced that it was delighted with the appointment of Axlab A/S as its exclusive distribution partner for Denmark and Sweden. The agreement provides Axlab with the right to sell Sienna’s product to pathology laboratories where it will be used as an adjunct to urine cytology to assist pathologists and urologists in their diagnosis of bladder cancer.


25/09/2017

Sienna Cancer Diagnostics Inks Distribution Agreement with Axlab

On Monday 25 September, Sienna announced that it has entered an agreement that retains Axlab as its exclusive distribution partner for Denmark and Sweden.


25/09/2017

Sienna Cancer Diagnostics to Launch its in-vitro Test in Denmark and Sweden

This article outlines the new distribution agreement in Denmark and Sweden to accelerate the global roll out of Sienna’s hTERT IVD test. Sienna’s test help urologist detect bladder cancer.


25/09/2017

Sienna: Axlab Bladder Test Distributor for Denmark, Sweden

On Monday 25 September, Sienna announced that it was delighted with the appointment of Axlab A/S as its exclusive distribution partner for Denmark and Sweden. This is the first distribution agreement to be signed since Sienna’s ASX listing and will broaden and accelerate the global roll out of its in-vitro diagnostic (IVD) test.


08/09/2017

Daily News on ASX-listed Biotechnology Companies

In this article David Neate, Sienna’s largest shareholder, says he has increased his substantial shareholding in Sienna from 17,002,970 shares (9.43%) to 18,852,970 shares (10.46%). Mr Neate bought 1,850,000 shares on market on August 3 and September 5, 2017 for $296,678 or 16 cents a share.


25/08/2017

Dr Boreham’s Crucible: Sienna Cancer Diagnostics

In this edition of Dr Boreham’s Crucible, Tim Boreham takes a critical look at Sienna’s recent initial public offer while outlining the enormous potential of Sienna’s simple diagnosis tool for pathology labs.


21/08/2017

Sienna Cancer Diagnostics Eyes U.S. for Bladder Cancer IVD following Australian IPO

After raising A$4.6 million through its initial public offering on the Australian Securities Exchange, Sienna Cancer Diagnostics is gearing up to launch the first test to detect telomerase in clinical samples.


31/07/2017

Sienna IPO Raises $4.6m to List on Thursday

Sienna Cancer Diagnostics raised $4.6 million in its initial public offer at 20 cents a share and expects to list on the ASX under the code SDX on Thursday, August 3.


14/07/2017

Sink or Swim podcast: Episode 2 - GetSwift Ltd and Robo 3D Ltd

In this episode of Sink or Swim, OzFinancial CEO Patrick Nelson discusses valuations with Matthew Lindh, Managing Director at Sequoia Corporate Finance. Matthew uses Sienna as an example in his explanation. The Matthew Lindh interview starts at 21:10 into the podcast.

 


30/06/2017

Biotech Company Focused on the Development and Commercialisation of Novel IVD Tests

Australia's Health Professional Radio audio interview with Sienna CEO, Matthew Hoskin in which Sienna's hTERT test is explained to medical professionals.

 

 


20/06/2017

Sienna Cancer Diagnostics not without risk

This article covers Sienna Cancer Diagnostics’ plan to list on the ASX in the following month. Having passed a big hurdle by registering with the US Food & Drug Administration and established distribution partners in the US and Europe, could provide quick access to the Company’s target market.


15/06/2017  

Sienna Develops Early Cancer Detection Test

Sharecafe article talking about the upcoming Sienna IPO and the fact that Sienna is unique among its biotech peers because of existing revenues and regulatory filings.

13/06/2017

 

Sienna Cancer Diagnostics (ASX:SDX) CEO, Matthew Hoskin, discusses its diagnostic technology and upcoming IPO

4-traders article covering Matthew Hoskin's interview with Carolyn Herbert of Finance News Network.

 

 

 


Sign up for updates